Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an announcement.
IRLAB Therapeutics AB held its Annual General Meeting on June 11, 2025, where several key resolutions were adopted. The meeting approved the financial statements for 2024, decided to carry forward the company’s results without distributing dividends, and re-elected board members and auditors. Additionally, the board’s remuneration was set with a conditional reduction until certain financial targets are met. The meeting also authorized the board to issue new shares or warrants with preferential rights for shareholders.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a company operating in the pharmaceutical industry, focusing on the development of novel treatments for neurological disorders. The company is known for its research and development efforts aimed at addressing unmet medical needs in the field of neurology.
Average Trading Volume: 52,859
Current Market Cap: SEK368.3M
For a thorough assessment of IRLAB.A stock, go to TipRanks’ Stock Analysis page.